Clinical trials: HER2-Negative Breast Carcinoma
Breast Neoplasms
Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
The combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy is the standard first-line treatment for advanced HR+ (hormone receptor-positive)/HER2- (human epidermal growth factor receptor 2-negative)…
- Trial name
- NCT07162259
- Testing
- First-line T-DXd followed by SG upon disease progression, First-line SG followed by T-DXd upon progression
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yan Xue
Breast Cancer
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
This was a randomized, double-blind, placebo-controlled phase 2 clinical trial comparing the overall survival of women with advanced or metastatic HER2-negative breast cancer who received treatment with capecitabine in…
- Trial name
- NCT02120417
- Testing
- Ruxolitinib, Capecitabine
- Where
- 106 sites in United States, France and 4 more
- Volunteers
- 149 people
- Sponsor
- Incyte Corporation
Early Breast Cancer, Adjuvant Therapy
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
This study aims to evaluate the efficacy and safety of adjuvant endocrine therapy combined with dalpiciclib at different doses and durations in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast…
- Conditions
- Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast Cancer
- Trial name
- NCT07101159
- Testing
- Dalpiciclib, Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
- Volunteers
- 200 people
- Sponsor
- Fujian Cancer Hospital
Breast Cancer
Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma
The present study is a transnational study in patients with high risk recurrent breast cancer who receive adjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel or paclitaxel.
- Trial name
- NCT04365790
- Where
- Greece
- Volunteers
- 500 people
- Sponsor
- Hellenic Cooperative Oncology Group
Metastatic Breast Cancer
SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer
This study tests the hypothesis that SU11248 can delay tumor progression after tumor mass reduction by taxanes. This is a dual-arm open-label randomized multicenter phase II clinical trial with 2:1 randomization evaluating the…
- Trial name
- NCT00270413
- Testing
- SU11248
- Where
- 13 sites in Belgium
- Volunteers
- 19 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
HER2 Negative Breast Carcinoma Expressing CEA
ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA
Main objective: To determine the optimal molar doses of the biospecific antibody TF2 and 68 Ga-IMP-288 and the optimal time for pretargeting for immuno-PET in patients with breast carcinoma.
- Trial name
- iTEPsein (NCT01730612)
- Testing
- TF2 - 68 Ga-IMP-288:
- Where
- 2 sites in France
- Volunteers
- 23 people
- Sponsor
- Nantes University Hospital
Breast Cancer
FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer
Phase II, multicenter, single arm trial to assess the feasibility of first line ribociclib in combination with a non steroidal aromatase inhibitor in women or men aged 70 years-old or older, with hormone receptor positive/HER2…
- Trial name
- FACILE (NCT03944434)
- Testing
- Ribociclib, Aromatase Inhibitors, non steroideal, LHRH agonist
- Where
- Italy
- Volunteers
- 116 people
- Sponsor
- Fondazione Sandro Pitigliani
Metastatic Breast Cancer
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
This study is a randomized, open-label, multicentric, phase III trial conducted in patients receiving aromatase inhibitor and palbociclib as first line therapy for estrogen receptor (ER)-positive HER2-negative metastatic breast…
- Trial name
- PADA-1 (NCT03079011)
- Testing
- Palbociclib 125mg, Aromatase Inhibitors, Fulvestrant Injectable Product
- Where
- 82 sites in France
- Volunteers
- 1,017 people
- Sponsor
- UNICANCER
Triple Negative Breast Neoplasms
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab
Phase III randomized trial of the anti-PD-L1 antibody avelumab as adjuvant or post-neoadjuvant treatment for high-risk triple negative breast cancer patients.
- Trial name
- A-Brave (NCT02926196)
- Testing
- MSB0010718C
- Where
- 70 sites in Italy, United Kingdom
- Volunteers
- 474 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Metastatic Breast Cancer, Advanced Breast Cancer
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)
The goal of this study is to evaluate the extended Overall Survival (OS) from PARSIFAL trial - NCT02491983 focused on the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with Human…
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Luminal Breast Cancer, HER2-negative Breast Cancer
- Trial name
- NCT06525675
- Testing
- Fulvestrant Injectable Product, Letrozole 2.5mg, Palbociclib 125mg
- Where
- 36 sites in Czechia, France and 4 more
- Volunteers
- 419 people
- Sponsor
- MedSIR
Hormone Receptor Positive HER-2 Negative Breast Cancer
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
This study will evaluate the efficacy and safety of docetaxel plus carboplatin (TCb) regimen compared with conventional chemotherapy regimen (epirubicin plus cyclophosphamide followed by docetaxel, EC-T) regimen as adjuvant…
- Trial name
- NCT05901428
- Testing
- Docetaxel, Carboplatin, Epirubicin
- Where
- China
- Volunteers
- 1,736 people
- Sponsor
- Fudan University
HER2-negative Metastatic Breast Cancer
Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of post-second-line metastatic breast cancer.
- Trial name
- NCT06533722
- Testing
- Gemcitabine, Vinorelbine, or Eribulin
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Premenopausal Breast Cancer
Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer
This is an open-label, single-arm, multicenter, pilot study of pembrolizumab, exemestane, and leuprolide for subjects being resistant for front-line hormonal therapy for inoperable locally advanced or metastatic hormonal receptor…
- Trial name
- PEER (NCT02990845)
- Testing
- Pembrolizumab/ Exemestane/ Leuprolide
- Where
- Taiwan
- Volunteers
- 16 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer
Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer
Neoadjuvant chemotherapy (NAC) is increasingly used for early-stage operable breast cancer. Response of breast cancer to NAC is correlated with survival: patients who obtain greatest survival advantage are those who attain…
- Trial name
- BERNAQ (NCT02365805)
- Testing
- Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel, Epirubicin + Cisplatin + Fluorouracil, Docetaxel + Ciclofosfamide
- Where
- 7 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Breast Cancer
Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer
The aim of this study is to evaluate the safety and efficacy of anti PD-L1 antibody + anti CTLA-4 antibody in combination with hormone therapy in patients with hormone receptor positive HER2-negative recurrent or metastatic…
- Trial name
- NCT03430466
- Testing
- Durvalmab&Tremelimumab&Fulvestrant
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Kyoto Breast Cancer Research Network
Early Breast Cancer
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
This is a multi-center, open-label Phase II randomized pre-surgical pharmacodynamics study.
- Trial name
- MONALEESA-1 (NCT01919229)
- Testing
- LEE011 (ribociclib), letrozole
- Where
- 7 sites in United States, Singapore and 1 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer.
- Conditions
- Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Breast Cancer
- Trial name
- CAPELA (NCT07222215)
- Testing
- Capecitabine, Elacestrant
- Where
- United States
- Volunteers
- 297 people
- Sponsor
- Kristina A. Fanucci
Breast Cancer
Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer
This study will evaluate the efficacy and toxicity of docetaxel-epirubicin combination plus bevacizumab as first line treatment in patients with metastatic and HER2 negative breast cancer.
- Trial name
- NCT00705315
- Testing
- Docetaxel, Epirubicin, Bevacizumab
- Where
- 10 sites in Greece
- Volunteers
- 46 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy…
- Trial name
- NCT06086340
- Testing
- Palbociclib, Aromatase Inhibitor
- Where
- United States
- Volunteers
- 779 people
- Sponsor
- Pfizer
Breast Cancer
Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer
This is a feasibility study evaluating the use of a mathematical model to predict response to standard neoadjuvant anthracycline / taxane based chemotherapy in patients with breast cancer.
- Trial name
- NCT03983538
- Testing
- Mathematical modeling to predict response to chemotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New Mexico Cancer Research Alliance
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.